Dolasik I - Search Results

1

Decreased serum heat shock protein 60 levels in newly diagnosed immune thrombocytopenia patients.

Dolasik I, Birtas Atesoglu E, Tarkun P, Mehtap O, Keski H, Dogru A, Hacihanefioglu A. Dolasik I, et al. Platelets. 2015;26(3):220-3. doi: 10.3109/09537104.2014.898746. Epub 2014 Apr 21. Platelets. 2015. PMID: 24749912 Free article.

2

IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.

Mehtap O, Atesoglu EB, Tarkun P, Hacihanefioglu A, Dolasik I, Musul MM. Mehtap O, et al. Among authors: dolasik i. J Postgrad Med. 2014 Apr-Jun;60(2):141-4. doi: 10.4103/0022-3859.132319. J Postgrad Med. 2014. PMID: 24823512

3

The effect of metformin on mean platelet volume in dıabetıc patients.

Dolasık I, Sener SY, Celebı K, Aydın ZM, Korkmaz U, Canturk Z. Dolasık I, et al. Platelets. 2013;24(2):118-21. doi: 10.3109/09537104.2012.674165. Epub 2012 Apr 12. Platelets. 2013. PMID: 22494325 Free article.

4

Evaluation of cardiotoxicity via speckle-tracking echocardiography in patients treated with anthracyclines.

Dogru A, Cabuk D, Sahin T, Dolasik I, Temiz S, Uygun K. Dogru A, et al. Among authors: dolasik i. Onkologie. 2013;36(12):712-6. doi: 10.1159/000356850. Epub 2013 Nov 20. Onkologie. 2013. PMID: 24356562 Clinical Trial.

5

Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.

Aksu G, Ensaroglu F, Dolasik I, Temiz S, Halis H, Sener SY, Kaya A, Uygun K. Aksu G, et al. Among authors: dolasik i. J BUON. 2010 Oct-Dec;15(4):798-9. J BUON. 2010. PMID: 21229650 No abstract available.

6

Evaluation of the efficacy of aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life with functional living index emesis.

Aksu G, Dolaşık I, Ensaroğlu F, Sener SY, Aydın FH, Temiz S, Canoğlu D, Uygun K. Aksu G, et al. Among authors: dolasik i. Balkan Med J. 2013 Mar;30(1):64-7. doi: 10.5152/balkanmedj.2012.087. Epub 2013 Mar 1. Balkan Med J. 2013. PMID: 25207071 Free PMC article.

7

An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis.

Uz B, Dolasik I. Uz B, et al. Among authors: dolasik i. Leuk Res Rep. 2015 Dec 3;5:1-2. doi: 10.1016/j.lrr.2015.11.001. eCollection 2016. Leuk Res Rep. 2015. PMID: 26870658 Free PMC article.

8

Chronic lymphocytic lymphoma and concomitant renal cell carcinoma (Clear Cell Type): Review of the literature.

Uz B, Dolasik I, Ucer O, Dagli AF, Simsek S. Uz B, et al. Among authors: dolasik i. Leuk Res Rep. 2016 Jun 24;6:8-10. doi: 10.1016/j.lrr.2016.06.002. eCollection 2016. Leuk Res Rep. 2016. PMID: 27453815 Free PMC article.

9

Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib.

Uz B, Dolasik I. Uz B, et al. Among authors: dolasik i. Ann Pharmacother. 2016 Apr;50(4):334-5. doi: 10.1177/1060028015627663. Epub 2016 Feb 2. Ann Pharmacother. 2016. PMID: 26839006 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters